AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
13.73
+0.30 (2.23%)
At close: Jun 26, 2026, 4:00 PM EDT
13.81
+0.08 (0.58%)
After-hours: Jun 26, 2026, 4:10 PM EDT
AgomAb Therapeutics NV Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AgomAb Therapeutics NV stock have an average target of 28.39, with a low estimate of 10.55 and a high estimate of 36. The average target predicts an increase of 106.77% from the current stock price of 13.73.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AgomAb Therapeutics NV stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 |
| Buy | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Initiates $35 | Buy | Initiates | $35 | +154.92% | Jun 22, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $28 → $11 | Buy | Maintains | $28 → $11 | -23.16% | May 18, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Initiates $32 | Buy | Initiates | $32 | +133.07% | Mar 3, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $36 | Buy | Initiates | $36 | +162.20% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.81
from -167.76
EPS Next Year
-2.00
from -1.81
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.62 | -1.55 | |
| Avg | -1.81 | -2.00 | |
| Low | -2.05 | -2.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.